| scholarly article | Q13442814 |
| P50 | author | Rino Rappuoli | Q2154243 |
| Antonio Cassone | Q89184800 | ||
| P2093 | author name string | Maria Romano | |
| Paolo Costantino | |||
| Elena Mori | |||
| Antonella Torosantucci | |||
| Daniela Proietti | |||
| Francesco Berti | |||
| Marta Tontini | |||
| Carla Bromuro | |||
| Paola Chiani | |||
| P2860 | cites work | Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis | Q77399512 |
| Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey | Q80052810 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges | Q24625384 | ||
| Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study | Q29616607 | ||
| Epidemiology of invasive candidiasis: a persistent public health problem | Q29616758 | ||
| Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. | Q30366836 | ||
| Structural characterization of beta-D-(1 --> 3, 1 --> 6)-linked glucans using NMR spectroscopy | Q30619650 | ||
| Protection by anti-beta-glucan antibodies is associated with restricted beta-1,3 glucan binding specificity and inhibition of fungal growth and adherence | Q30862390 | ||
| Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. | Q34085884 | ||
| Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine | Q34131697 | ||
| Curdlan and other bacterial (1-->3)-beta-D-glucans | Q34409845 | ||
| The structure and synthesis of the fungal cell wall | Q34559828 | ||
| Fungal β-Glucans and Mammalian Immunity | Q35538040 | ||
| MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine | Q35546445 | ||
| Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. | Q35556297 | ||
| Is a vaccine needed against Candida albicans? | Q36099098 | ||
| An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo | Q36313815 | ||
| A novel glyco-conjugate vaccine against fungal pathogens | Q36402820 | ||
| Advances in combating fungal diseases: vaccines on the threshold | Q36406460 | ||
| Prospects for development of vaccines against fungal diseases | Q36527215 | ||
| Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine | Q36690302 | ||
| Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis | Q36869958 | ||
| Fungal vaccines: real progress from real challenges | Q37067893 | ||
| Safety of MF59 adjuvant | Q37156975 | ||
| Generating cell surface diversity in Candida albicans and other fungal pathogens | Q37212275 | ||
| The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. | Q40455646 | ||
| Candida albicans mannan-protein conjugate as vaccine candidate | Q44380966 | ||
| Anti-beta-glucan antibodies in healthy human subjects. | Q45134766 | ||
| Synthesis of glycoconjugate vaccines for Candida albicans using novel linker methodology | Q46669006 | ||
| A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens | Q46814402 | ||
| Synthesis and immunochemical studies on a Candida albicans cluster glycoconjugate vaccine | Q46944954 | ||
| Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. | Q51184875 | ||
| Determination of free amino groups in proteins by trinitrobenzenesulfonic acid | Q70066383 | ||
| A spectrophotometric assay for soluble and immobilized N-hydroxysuccinimide esters | Q70558363 | ||
| Analysis of the structural heterogeneity of laminarin by electrospray-ionisation-mass spectrometry | Q71295433 | ||
| Ultraviolet spectrophotometric determination of hexoses, pentoses, and uronic acids after their reactions with concentrated sulfuric acid | Q72321076 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Laminarin | Q423729 |
| [3)-beta-D-Glcp-(1->]15 | Q27131759 | ||
| beta-Glcp-(1->6)-{beta-Glcp-(1->6)-{[beta-Glcp-(1->3)]5}-[beta-Glcp-(1->3)]5}-[beta-Glcp-(1->3)]4-beta-Glcp | Q27131763 | ||
| P304 | page(s) | 2615-2623 | |
| P577 | publication date | 2010-01-21 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Beta-glucan-CRM197 conjugates as candidates antifungal vaccines | |
| P478 | volume | 28 |
| Q40541300 | 6-O-Branched Oligo-β-glucan-Based Antifungal Glycoconjugate Vaccines |
| Q42424566 | A Convergent Synthesis of 6-O-Branched β-Glucan Oligosaccharides. |
| Q58692952 | A Three Component Synthetic Vaccine Containing a β-Mannan T-Cell Peptide Epitope and a β-Glucan Dendritic Cell Ligand |
| Q43648622 | A β-mannan trisaccharide conjugate vaccine aids clearance of Candida albicans in immunocompromised rabbits |
| Q37918556 | Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations |
| Q36757877 | Adjuvanticity of a recombinant calreticulin fragment in assisting anti-β-glucan IgG responses in T cell-deficient mice |
| Q38264288 | Adjuvants and delivery systems for antifungal vaccines: current state and future developments |
| Q36003400 | Antibody Peptide based antifungal immunotherapy |
| Q91831875 | Antifungal-demelanizing properties and RAW264.7 macrophages stimulation of glucan sulfate from the mycelium of the mushroom Ganoderma lucidum |
| Q48131354 | Automated glycan assembly of branched β-(1,3)-glucans to identify antibody epitopes |
| Q45832515 | Automated solid-phase synthesis of a β-(1,3)-glucan dodecasaccharide |
| Q90212318 | CD4+ T Cell Regulation of Antibodies Cross-Reactive with Fungal Cell Wall-Associated Carbohydrates after Pneumocystis murina Infection |
| Q35075750 | CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine |
| Q38130314 | Candida albicans, plasticity and pathogenesis |
| Q38222636 | Candida antigens and immune responses: implications for a vaccine. |
| Q94465687 | Carbohydrate Conjugates in Vaccine Developments |
| Q42088304 | Caspase-8 modulates dectin-1 and complement receptor 3-driven IL-1β production in response to β-glucans and the fungal pathogen, Candida albicans |
| Q38066728 | Designing a new antifungal glycoconjugate vaccine |
| Q86738262 | Development of vaccines for Candida albicans: fighting a skilled transformer |
| Q90303798 | Effects of immune suppression in murine models of disseminated Candida glabrata and Candida tropicalis infection and utility of a synthetic peptide vaccine |
| Q34030615 | Global Warming Will Bring New Fungal Diseases for Mammals |
| Q41901935 | Host defense pathways against fungi: the basis for vaccines and immunotherapy |
| Q38067451 | Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections |
| Q42553468 | Immunity to fungi |
| Q38635409 | Immunotherapy of Fungal Infections |
| Q39201536 | Linear Epitopes of Paracoccidioides brasiliensis and Other Fungal Agents of Human Systemic Mycoses As Vaccine Candidates |
| Q36158337 | New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges |
| Q41660949 | Overview of β-Glucans from Laminaria spp.: Immunomodulation Properties and Applications on Biologic Models |
| Q56884992 | Phage vaccines displaying YGKDVKDLFDYAQE epitope induce protection against systemic candidiasis in mouse model |
| Q53701548 | Potential targets for next generation anti-microbial glycoconjugate vaccines. |
| Q51696552 | Preclinical studies on new proteins as carrier for glycoconjugate vaccines. |
| Q28829950 | Protection against Experimental Melioidosis with a Synthetic manno-Heptopyranose Hexasaccharide Glycoconjugate |
| Q40172806 | Pseudogymnoascus destructans transcriptome changes during white-nose syndrome infections. |
| Q90246288 | Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development |
| Q36179629 | Recent progress in vaccines against fungal diseases |
| Q34259665 | Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis |
| Q26782272 | Studies of Immune Responses in Candida vaginitis |
| Q21131150 | Surface architecture of histoplasma capsulatum |
| Q36331649 | Synthesis and immunological studies of linear oligosaccharides of β-glucan as antigens for antifungal vaccine development |
| Q53683158 | The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future. |
| Q51699904 | The evaluation of β-(1 → 3)-nonaglucoside as an anti-Candida albicans immune response inducer. |
| Q38038044 | Universal fungal vaccines: could there be light at the end of the tunnel? |
| Q27009819 | Vaccine immunity against fungal infections |
| Q35161720 | Vaccines for invasive fungal infections |
| Q36147010 | Vaccines in the treatment of invasive candidiasis |
| Q34097250 | Yeast killer toxin-like candidacidal Ab6 antibodies elicited through the manipulation of the idiotypic cascade |
Search more.